{"cik":1645460,"taxonomy":"us-gaap","tag":"LongTermDebt","label":"Long-term Debt","description":"Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.","entityName":"Cue Biopharma, Inc.","units":{"USD":[{"end":"2022-03-31","val":9861000,"accn":"0000950170-22-008990","fy":2022,"fp":"Q1","form":"10-Q","filed":"2022-05-10","frame":"CY2022Q1I"},{"end":"2022-06-30","val":9913000,"accn":"0000950170-22-014747","fy":2022,"fp":"Q2","form":"10-Q","filed":"2022-08-04","frame":"CY2022Q2I"},{"end":"2022-09-30","val":9000000,"accn":"0000950170-22-024991","fy":2022,"fp":"Q3","form":"10-Q","filed":"2022-11-14","frame":"CY2022Q3I"},{"end":"2022-12-31","val":8000000,"accn":"0000950170-23-008927","fy":2022,"fp":"FY","form":"10-K","filed":"2023-03-21","frame":"CY2022Q4I"},{"end":"2023-03-31","val":7000000,"accn":"0000950170-23-019646","fy":2023,"fp":"Q1","form":"10-Q","filed":"2023-05-09","frame":"CY2023Q1I"},{"end":"2023-06-30","val":6000000,"accn":"0000950170-23-039770","fy":2023,"fp":"Q2","form":"10-Q","filed":"2023-08-08","frame":"CY2023Q2I"},{"end":"2023-09-30","val":5000000,"accn":"0000950170-23-058838","fy":2023,"fp":"Q3","form":"10-Q","filed":"2023-11-03","frame":"CY2023Q3I"},{"end":"2023-12-31","val":4000000,"accn":"0000950170-24-038059","fy":2023,"fp":"FY","form":"10-K","filed":"2024-03-28","frame":"CY2023Q4I"},{"end":"2024-03-31","val":3000000,"accn":"0000950170-24-056838","fy":2024,"fp":"Q1","form":"10-Q","filed":"2024-05-09","frame":"CY2024Q1I"},{"end":"2024-06-30","val":2000000,"accn":"0000950170-24-096967","fy":2024,"fp":"Q2","form":"10-Q","filed":"2024-08-14","frame":"CY2024Q2I"},{"end":"2024-09-30","val":1000000,"accn":"0000950170-24-127005","fy":2024,"fp":"Q3","form":"10-Q","filed":"2024-11-14","frame":"CY2024Q3I"}]}}